These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12534945)

  • 1. Bacterial otitis media: current vaccine development strategies.
    Cripps AW; Kyd J
    Immunol Cell Biol; 2003 Feb; 81(1):46-51. PubMed ID: 12534945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Otitis media: recent advances in otitis media vaccine development and model systems.
    Zahid A; Wilson JC; Grice ID; Peak IR
    Front Microbiol; 2024; 15():1345027. PubMed ID: 38328427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for a vaccine against otitis media.
    Cripps AW; Otczyk DC
    Expert Rev Vaccines; 2006 Aug; 5(4):517-34. PubMed ID: 16989632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial otitis media: a vaccine preventable disease?
    Cripps AW; Otczyk DC; Kyd JM
    Vaccine; 2005 Mar; 23(17-18):2304-10. PubMed ID: 15755616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era.
    Pumarola F; Marès J; Losada I; Minguella I; Moraga F; Tarragó D; Aguilera U; Casanovas JM; Gadea G; Trías E; Cenoz S; Sistiaga A; García-Corbeira P; Pirçon JY; Marano C; Hausdorff WP
    Int J Pediatr Otorhinolaryngol; 2013 Aug; 77(8):1231-6. PubMed ID: 23746414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Middle ear secretory capacity after acute otitis media caused by Streptococcus pneumoniae, Moraxella catarrhalis, non-typeable or type B Haemophilus influenzae. A comparative analysis based on goblet cell density.
    Cayé-Thomasen P; Hermansson A; Tos M; Prellner K
    Acta Otolaryngol Suppl; 2000; 543():54-5. PubMed ID: 10908976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges.
    Murphy TF
    Expert Rev Vaccines; 2005 Dec; 4(6):843-53. PubMed ID: 16372880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
    Prymula R; Peeters P; Chrobok V; Kriz P; Novakova E; Kaliskova E; Kohl I; Lommel P; Poolman J; Prieels JP; Schuerman L
    Lancet; 2006 Mar; 367(9512):740-8. PubMed ID: 16517274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress with Moraxella catarrhalis antigens as vaccine candidates.
    Mawas F; Ho MM; Corbel MJ
    Expert Rev Vaccines; 2009 Jan; 8(1):77-90. PubMed ID: 19093775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of various respiratory viruses in the middle ear during acute otitis media.
    Heikkinen T; Thint M; Chonmaitree T
    N Engl J Med; 1999 Jan; 340(4):260-4. PubMed ID: 9920949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against middle-ear bacterial and viral pathogens.
    Giebink GS
    Ann N Y Acad Sci; 1997 Dec; 830():330-52. PubMed ID: 9616694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.
    Murphy TF
    Clin Vaccine Immunol; 2015 May; 22(5):459-66. PubMed ID: 25787137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panel 8: Vaccines and immunology.
    Alderson MR; Murphy T; Pelton SI; Novotny LA; Hammitt LL; Kurabi A; Li JD; Thornton RB; Kirkham LS
    Int J Pediatr Otorhinolaryngol; 2020 Mar; 130 Suppl 1(Suppl 1):109839. PubMed ID: 31948716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine.
    Best EJ; Walls T; Souter M; Neeff M; Anderson T; Salkeld L; Ahmad Z; Mahadevan M; Walker C; Murdoch D; Mills N
    Vaccine; 2016 Jul; 34(33):3840-7. PubMed ID: 27265454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the development and use of viral and bacterial vaccines for the prevention of acute otitis media.
    Greenberg DP
    Allergy Asthma Proc; 2001; 22(6):353-7. PubMed ID: 11775392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprophylaxis of otitis media.
    Giebink GS
    Adv Exp Med Biol; 1991; 303():149-58. PubMed ID: 1805562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyp and fibrous adhesion formation in acute otitis media caused by non-typeable or type b Haemophilus influenzae or Moraxella catarrhalis.
    Cayé-Thomasen P; Tos M
    Acta Otolaryngol; 2000 Oct; 120(7):810-4. PubMed ID: 11132712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of myringosclerosis during acute otitis media caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a clinical otomicroscopical study using the rat model.
    Raustyte G; Hermansson A
    Medicina (Kaunas); 2005; 41(8):661-7. PubMed ID: 16160414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.